PubRank

Michael F McDermott

Author PubWeight™ 83.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004 13.55
2 Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004 7.07
3 Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009 5.84
4 Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003 3.86
5 Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002 2.58
6 p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009 2.44
7 A proposed classification of the immunological diseases. PLoS Med 2006 2.43
8 Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008 2.17
9 Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008 1.61
10 Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 2002 1.54
11 Inflammasomes and autoimmunity. Trends Mol Med 2010 1.53
12 Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003 1.51
13 Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum 2012 1.39
14 Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis 2013 1.37
15 The role of the NLRP3 inflammasome in gout. J Inflamm Res 2011 1.21
16 SPINK1 is a susceptibility gene for fibrocalculous pancreatic diabetes in subjects from the Indian subcontinent. Am J Hum Genet 2002 1.19
17 Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr Opin Rheumatol 2012 1.15
18 Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008 1.13
19 Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford) 2010 1.13
20 Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2004 1.08
21 The major histocompatibility complex origin. Immunol Rev 2004 1.07
22 Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol 2006 1.06
23 An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res 2009 1.02
24 Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009 1.02
25 Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des 2011 1.01
26 Multiplexing immunoassays for cytokine detection in the serum of patients with rheumatoid arthritis: lack of sensitivity and interference by rheumatoid factor. Clin Exp Rheumatol 2012 0.99
27 Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009 0.98
28 Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008 0.96
29 Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis 2010 0.96
30 NOD-like receptors and inflammation. Arthritis Res Ther 2008 0.95
31 Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-kappaB activation. Arthritis Rheum 2005 0.93
32 Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract Res Clin Rheumatol 2012 0.92
33 The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 2005 0.91
34 The NLRP3 inflammasome, a target for therapy in diverse disease states. Eur J Immunol 2010 0.91
35 Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap). Biologics 2008 0.91
36 BMS-561392. Bristol-Myers Squibb. Curr Opin Investig Drugs 2003 0.87
37 Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 2012 0.86
38 Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). J Inflamm Res 2010 0.84
39 Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes. Expert Rev Clin Immunol 2010 0.84
40 The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self. Semin Immunopathol 2007 0.83
41 First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). PLoS One 2013 0.83
42 An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002 0.83
43 Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther 2010 0.83
44 Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) or familial Hibernian fever: presentation in a four-day-old infant. J Clin Rheumatol 2008 0.82
45 Improving pediatric asthma care through surveillance: the Illinois Emergency Department Asthma Collaborative. Pediatrics 2006 0.81
46 Is caspase 1 central to activation of interleukin-1? Joint Bone Spine 2011 0.81
47 Proteolytic activation of the cytotoxic phenotype during human NK cell development. J Immunol 2009 0.81
48 Differential cytokine secretion results from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients. Cell Immunol 2011 0.80
49 Periodic fever syndrome and autoinflammatory diseases. F1000 Med Rep 2010 0.80
50 Inflammation: canakinumab for the cryopyrin-associated periodic syndromes. Nat Rev Rheumatol 2009 0.80
51 Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism. Nat Clin Pract Rheumatol 2008 0.77
52 Fifth International Congress on Familial Mediterranean Fever and Systemic Autoinflammatory Diseases. Expert Rev Clin Immunol 2008 0.77
53 A novel mutation in the third extracellular domain of the tumor necrosis factor receptor 1 in a Finnish family with autosomal-dominant recurrent fever. Arthritis Rheum 2002 0.77
54 Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene. Ann Rheum Dis 2013 0.77
55 Lessons from anti-TNF biologics: infliximab failure in a TRAPS family with the T50M mutation in TNFRSF1A. Adv Exp Med Biol 2011 0.76
56 Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond. Semin Immunopathol 2015 0.75
57 Lessons from characterization and treatment of the autoinflammatory syndromes. Curr Opin Rheumatol 2016 0.75
58 The asthma emergency department visit: treating a crisis in the midst of uncontrolled disease. Ann Allergy Asthma Immunol 2008 0.75